Set against these seemingly discrepant results are several studies showing that pharmacologic activation of Nrf2 protects against diabetes and NAFLD: these include the findings that treatment with the triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO)-methyl ester (bardoxolone methyl) ameliorates diabetes and hepatic steatosis in HF-fed mice29, 30 and that treatment with CDDO-imidazole attenuates diabetes in Leprdb/db mice.31 Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.